Inhibiteur RAD51 B02, > = 98 %(HPLC)

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

RAD51 Inhibitor B02 has been used:to test its effect on the polar body extrusion (PBE) rate in porcine oocytes for RAD51 inhibition in porcine embryos as RAD51 inhibitor and to test its effect on targeted nucleotide substitution (TNS) in induced pluripotent stem cells (iPSCs)

Biochem/physiol Actions

B02 (3-(Phenylmethyl)-2-[(1E)-2-(3-pyridinyl)ethenyl]-4(3H)-quinazolinone), a pyridinylvinyl-quinazolinone compound is cell-permeable. B02 inhibits human RAD51 recombinase and subsequent nucleofilaments formation. It halts homologous recombination (HR) repair events in cancer cells. B02 favors apoptosis in multiple myeloma and is crucial for sensitizing them to doxorubicin.

Packaging

5, 25 mg in glass bottle